Table 3.

Phase II trial tested sorafenib in DTC.

Phase II trials of Sorafenib in DTC
Reference	Patients (n)	Partial Response	Disease stabilization	mPFS (weeks)	Reference
Gupta-Abramson et al., 2008	30	23℅	53%	79	(61)
Kloss et al., 2009	41	15℅	56℅	60	(62)
Hoftijzer et al., 2009	31	25℅	34℅	58	(63)
Ahmed et al., 2011	19	25℅	68%	84	(64)